A sign is posted in front of the 23andMe headquarters in Sunnyvale, California, on Feb. 1, 2024. Anne Wojcicki, CEO of 23andMe, has submitted a proposal to take the genetic testing company private as its stock price continues to hover below $1. Wojcicki said she was prepared to acquire all of 23andMe's outstanding shares of common stock in cash for 40 cents per share, according to a Wednesday filing with the U.S. Securities and Exchange Commission. She expressed interest in acquiring the company in April, s ...

SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the first quarter of fiscal year 2025 (FY2025) after the market closes on Thursday, August 8, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's ...

SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the first quarter of fiscal year 2025 (FY2025) after the market closes on Thursday, August 8, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's ...

The de-identified data from the study will be made available to approved researchers, and access to the scientific database will be available to nonprofit researchers and institutions at no cost. Behind every devastating statistic are people from communities across the U.S. impacted by lung cancer. Through this collaboration, advocacy organizations, lung cancer survivors and advocates, and 23andMe hope ultimately to help advance research toward finding a cure for this disease. "Studying the genetics of lung ...

Sobering lung cancer statistics only tell part of the story Despite advances in treatment options, lung cancer remains a critical area of unmet need: Behind every devastating statistic are people from communities across the U.S. impacted by lung cancer. Through this collaboration, advocacy organizations, lung cancer survivors and advocates, and 23andMe hope ultimately to help advance research toward finding a cure for this disease. "Studying the genetics of lung cancer can help us understand risks, improve ...

SOUTH SAN FRANCISCO, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading preventive health and therapeutics company, and Nightingale Health Plc, a pioneer in biomarker testing and risk prediction, today announced a strategic collaboration to pilot Nightingale Health's clinicallyvalidated and cost-effective blood metabolomics panel with a cohort of 23andMe members. 23andMe currently offers its annual members the option for blood testing and provides interactive tools like He ...

Core Insights - 23andMe and Nightingale Health have announced a strategic collaboration to pilot a blood metabolomics panel with 23andMe members, aiming to enhance preventive health measures and risk prediction [1][5][6] Group 1: Collaboration Details - The pilot will utilize Nightingale's Remote Health Check, which measures various biomarkers from a single blood sample, including cholesterols and fatty acids, to guide lifestyle interventions [2][5] - Up to 5,000 23andMe+ Premium and Total Health members will receive blood testing at no cost, allowing the companies to gather customer feedback on the testing process and data utility [4][5] Group 2: Technological Integration - The collaboration aims to combine the strengths of both companies, enhancing 23andMe's existing health services with Nightingale's advanced biomarker testing technology [6] - This partnership is expected to provide a comprehensive health assessment and continuous tracking of health progress for customers [5][6] Group 3: Company Vision - Both companies share a vision of empowering individuals to identify health risks and prevent diseases through proactive testing and lifestyle changes [5][6] - The collaboration is seen as a significant step in Nightingale Health's strategy to access the consumer health market [6]

Penny stocks are some of the most affordable investments on the market, valued at less than $5. They can hold a unique and intriguing position that can be highly profitable. However, despite their low prices, these stocks are often the riskiest to own. Many are still in the process of establishing themselves in their respective markets or lack a solid foundation for significant growth. That said, there are exceptions. These three penny stocks are loaded with growth potential and have exciting developments c ...

On Monday, the U.K,'s Information Commissioner's Office (ICO) and the Office of the Privacy Commissioner of Canada (OPC) announced their investigation into the genetic testing company, saying the organizations will leverage "the combined resources and expertise of their two offices." "This data breach had an international impact, and we look forward to collaborating with our Canadian counterparts to ensure the personal information of people in the U.K. is protected," said Edwards. Hackers broke into around ...

SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today released a new genetic Bipolar Disorder report (Powered by 23andMe Research) for 23andMe+ Premium members, informing them if they are at higher likelihood for being diagnosed with the condition. Bipolar disorder is a mental health condition that can cause extreme and unusual shifts in mood, energy, behavior and activity, ranging from highs (mania) to ...